Summit Hotel Properties, Inc. (INN) News
Filter INN News Items
INN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
INN News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest INN News From Around the Web
Below are the latest news stories about SUMMIT HOTEL PROPERTIES INC that investors may wish to consider to help them evaluate INN as an investment opportunity.
SUMMIT HOTEL PROPERTIES ANNOUNCES FOURTH QUARTER AND FULL YEAR 2024 EARNINGS RELEASE DATESummit Hotel Properties, Inc. (NYSE: INN) (the "Company") today announced that it will report financial results for the fourth quarter and full year of 2024 on Monday, February 24, 2025, after the market closes. |
FDA's Center for Veterinary Medicine Grants Innocan Pharma a Fee Waiver for 2025Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that the FDA's Center for Veterinary Medicine (CVM) has granted the Company a sponsor fee waiver for its LPT-CBD (Liposome Platform Technology-Cannabidiol) product for the second consecutive year. |
Innocan Pharma Announces Closing of Private Placement for Gross Proceeds of C$635,444.60Innocan Pharma Corporation (the "Company") (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) is pleased to announce that it has closed its previously announced non-brokered private placement offering (the "Offering") of units of the Company (the "Units"), pursuant to which the Company issued 3,177,223 Units at a price of C$0.20 per Unit (the "Offering Price") for aggregate gross proceeds of $635,444.60. |
Innocan Pharma Announces Private Placement of UnitsInnocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan") is pleased to announce that it intends to complete a non-brokered private placement of up to [3,500,000] units of the Company (the "Units") at a price of [C$0.20] per Unit for gross proceeds up to C$700,000 plus 15% over allotment options (the "Offering"). The Offering is expected to close on or around December 31, 2024. |
Innocan Pharma Provides its Annual "State of Research and Development" Update for 2024Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies and an owner of a proprietary intellectual property portfolio, is pleased to share its annual "State of Research and Development" update for 2024. This year, the Company achieved significant milestones in advancing research and development for its drug delivery platforms as well as its intellectual |
Summit Hotel Properties Announces Pending Acquisition of Two-Hotel Portfolio for $96 Million Through GIC Joint VentureSummit Hotel Properties, Inc. (NYSE: INN) (the "Company"), through its joint venture with GIC, today announced that it is under contract to acquire the 250-guestroom Hampton Inn Boston - Logan Airport and the 149-guestroom Hilton Garden Inn Tysons Corner for a combined purchase price of $96.0 million, or $241,000 per key. The purchase price represents an 8.8% capitalization rate based on forecasted 2024 net operating income and no meaningful capital expenditures are planned prior to the fourth q |
Innocan Pharma Announces Encouraging Results from a Safety Assessment Study of LPT-CBD on MinipigsInnocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to report positive results from a basic safety assessment study, evaluating LPT-CBD administered as a single injection in Göttingen minipigs. |
Innocan Pharma Reports Third Quarter 2024 Financial ResultsInnocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies, is pleased to announce its consolidated financial results for the three and nine-month periods ended September 30, 2024. |
How To Put $100 In Your Retirement Fund Each Month With Summit Hotel Properties StockSummit Hotel Properties, Inc. (NYSE:INN) is a publicly traded real estate investment trust focused on owning premium-branded lodging properties with efficient operating models primarily in the upscale segment of the lodging industry. The 52-week range ... |
Innocan to Direct Full Focus on Following Positive FDA Engagement and Significant Potential Market DemandInnocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, announced that it has taken the strategic decision to focus its development resources on advancing its groundbreaking Liposome Platform Technology-Cannabidiol (LPT-CBD), a monthly injectable treatment for chronic pain in both animals and humans. This decision follows encouraging progress with the U.S. Food and Drug Administration (FDA). |